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ABSTRACT
Our aim was to evaluate the potential cost-effectiveness of PET/CT with FES 
and 89Zr-trastuzumab compared to pathology to select first-line targeted treatment 
in metastatic breast cancer (MBC) patients with non-rapidly progressive disease. A 
previously published and validated model was extended and adapted for this analysis. 
Two alternative scenarios were compared. In the care as usual pathway first-line 
targeted treatment of MBC patients was assigned on the basis of pathology results, 
while in the intervention pathway treatment selection was based on the results from 
the PET/CT imaging. Costs, life years gained (LYG) and incremental cost-effectiveness 
ratios (ICER) were calculated. More MBC lesions were detected in the intervention 
pathway than in the care as usual pathway. The diagnostic costs to evaluate the 
receptor status and the treatment costs were higher in the intervention strategy, as 
were total costs and total LYG. The ICER for replacing biopsies with PET/CT imaging 
with FES and 89Zr-trastuzumab, assuming sensitivity of 77.1% and specificity of 80%, 
ranged from €71,000 to €77,000 per LYG. When assuming sensitivity of 80% and 
specificity of 76.7%, the ICER for replacing biopsies with PET/CT imaging with FES and 
89Zr-trastuzumab ranged from to €74,000 to €80,000 per LYG. The application of PET/
CT with FES and 89Zr-trastuzumab in first-line treatment selection for MBC patients 
has the potential to be a cost-effective intervention. Our analysis demonstrated that 
even a small increase in the sensitivity and the specificity of PET/CT can have a large 
impact on its potential cost-effectiveness.
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INTRODUCTION
Breast cancer can present in many different 
ways with regards to stage, phenotype, location, and 
heterogeneity of the disease. Many treatment options 
are available, and their efficacy is highly dependent on 
the disease characteristics. Treatment of non-rapidly 
progressive metastatic breast cancer (MBC) is stratified 
on the basis of the tumor expression of receptors that 
are targets for pharmacological intervention. Human 
epidermal growth factor receptor 2 (HER2-) and hormone 
receptor (HR–estrogen receptor (ER) and progesterone 
receptor (PR)) targeted and hormonal therapies are 
recommended for patients with tumors that express these 
receptors [1, 2]. Patients with negative receptor status 
(HER2- and HR-negative) of the metastatic disease do 
not respond to targeted therapy in general, therefore, 
chemotherapy remains as a treatment option [3, 4]. 
Targeted therapy for MBC can potentially prolong the 
survival of MBC patients [5], but can also be costly 
and may bring adverse effects. New targeted therapies 
regularly become available (e.g. palbociclib, pertuzumab) 
and a prior selection of patients is crucial to optimize 
outcomes of targeted therapy at acceptable costs. 
Moreover, this may also improve progression-free and 
overall survival [5], and further minimize adverse effects 
and avoid unnecessary harms and associated costs for 
those who do not respond.
Targeted treatment for MBC patients is currently 
selected and administered according to pathology results 
of tumor receptor status, often obtained from the primary 
tumor. However, pathology can often be inconclusive or 
insufficient regarding receptor expression [6], and receptor 
expression in the primary tumor or in a single metastatic 
lesion is not necessarily identical or reflects the receptor 
status of all metastases [7–11]. As an alternative positron 
emission tomography and computed tomography (PET/
CT) imaging with the tracers 16α-[18F]fluoro-17β-estradiol 
(FES) and zirconium-89-(89Zr)-trastuzumab has been 
proposed to evaluate the tumor ER and HER2 expression 
in MBC and thus guide the selection of patients who might 
benefit from targeted treatment [12–15].
Since molecular imaging with PET/CT is perceived 
as expensive and there is still uncertainty regarding its 
sensitivity and specificity, prior evaluation of its potential 
cost-effectiveness when applied to select first-line 
targeted treatment in MBC patients is warranted. Previous 
economic evaluations of PET/CT in MBC are limited to 
diagnosis of the disease [16, 17]. As a result, the potential 
cost-effectiveness of the application of molecular PET/CT 
imaging to select targeted treatment in MBC patients is 
unclear. Therefore, the aim of this study was to evaluate 
the potential cost-effectiveness of PET/CT with FES and 
89Zr-trastuzumab tracers compared to pathology testing 
to select first-line targeted treatment in MBC patients 
with non-rapidly progressive disease. We worked on a 
model including a “biopsy versus imaging” strategy for 
receptor status evaluation because we wanted to test the 
potential cost-effectiveness of PET/CT with FES and 89Zr-
trastuzumab as a one-stop shop for treatment selection 
in MBC. We limited our analysis to a few important 
treatment options to demonstrate proof of concept of 
potential cost-effectiveness of imaging, instead of working 
on a model including all new targeted therapies.
RESULTS
For baseline scenario 1 we assumed that the 
sensitivity of FES-PET/CT and 89Zr-trastuzumab PET/CT 
was set at 77.1% and the specificity was set at 80%, as this 
was the minimum at which PET/CT could demonstrate 
potential cost-effectiveness. For baseline scenario 2 we 
assumed that the sensitivity of FES-PET/CT and 89Zr-
trastuzumab PET/CT was set at 80% and the specificity 
was set at 76.7%, as this was the minimum at which PET/
CT could demonstrate potential cost-effectiveness. The 
results from the decision analytical model are presented 
in Table 1.
Health effects and costs
More MBC lesions were detected in the intervention 
pathway than in the care as usual pathway. The diagnostic 
costs to evaluate the receptor status and the treatment costs 
were also higher in the intervention strategy, as were total 
costs and total life years gained (LYG). The treatment with 
anastrozole and trastuzumab monotherapy was cheaper 
than the use of letrozole and trastuzumab combination 
therapy (trastuzumab and paclitaxel) (Table 1).
Cost-effectiveness
The incremental cost-effectiveness ratio (ICER) 
for replacing biopsies with PET/CT imaging with FES 
and 89Zr-trastuzumab for receptor status evaluation and 
treatment selection in MBC patients (assuming sensitivity 
of 77.1% and specificity of 80%) ranged from to €71,000 
to €77,000 per LYG if patients were treated with letrozole 
and trastuzumab combination therapy (trastuzumab 
and paclitaxel), or with anastrozole and trastuzumab 
monotherapy, respectively (baseline scenario 1, Table 1).
The ICER for replacing biopsies with PET/CT 
imaging with FES and 89Zr-trastuzumab for receptor 
status evaluation and treatment selection in MBC patients 
(assuming sensitivity of 80% and specificity of 76.7%) 
ranged from to €74,000 to €80,000 per LYG if patients 
were treated with letrozole and trastuzumab combination 
therapy (trastuzumab and paclitaxel), or with anastrozole 
and trastuzumab monotherapy, respectively (baseline 
scenario 2, Table 1).
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Sensitivity analyses
When the probabilities of inconclusive and 
unobtainable biopsies were set at their minimum values (i.e. 
10%), the minimum sensitivity and specificity of FES-PET/
CT and 89Zr-trastuzumab PET/CT, at which the intervention 
strategy was likely to be cost-effective were 90% and 
90.6%, respectively. For values of PET/CT sensitivity 
and specificity below 90% and 90.6%, respectively, the 
intervention strategy was dominated, because it was costlier 
and less effective than the care as usual. For even lower 
values of PET/CT sensitivity and specificity, below 70% 
and 80%, respectively, effectiveness was logically even 
less. This lack of effectiveness resulted in cost savings 
from avoided treatment costs as compared to care as usual 
(Supplementary Appendix A, Supplementary Tables A1 
and A2).
When the probabilities of inconclusive and 
unobtainable biopsies were set at 15%, the minimum 
sensitivity and specificity of FES-PET/CT and 89Zr-
trastuzumab PET/CT, at which the intervention strategy 
was likely to be cost-effective were 83% and 86%, 
respectively. Below these values for PET/CT sensitivity 
and specificity the intervention strategy was less effective 
than the care as usual (Supplementary Appendix A, 
Supplementary Tables A1 and A2).
When the probabilities of inconclusive and 
unobtainable biopsies were set at 20%, for values of 
PET/CT sensitivity and specificity below 77% and 80%, 
respectively, the intervention strategy was less effective 
than the care as usual (Supplementary Appendix A, 
Supplementary Tables A1 and A2).
When the probabilities of inconclusive and 
unobtainable biopsies were set at their maximum 
values (i.e. 30%), the minimum sensitivity, at which 
the intervention strategy was likely to be cost-effective 
was 59.6% and the corresponding specificity was 70%. 
Alternatively, the lowest specificity value for which the 
intervention strategy was still cost-effective than care 
as usual was 58.5 %, at a sensitivity of 70%. For values 
of PET/CT sensitivity and specificity below these, the 
intervention strategy was less effective than the care as 
usual (Supplementary Appendix A, Supplementary Tables 
A1 and A2).
Table 1: Simulation results for the care as usual and the intervention pathways for a hypothetical cohort of 1,000 
women
Care as usual Intervention Care as usual Intervention
Baseline scenario 1 Baseline scenario 2
Diagnosed MBCs
   Bone 228 234 228 235 
   Lung 199 203 199 204 
   Brain 65 66 65 66 
   Liver 159 163 159 163 
Cost of receptor status 
evaluation (in k€)
695 3,500 695 3,500
Cost of therapies (in k€)
   Chemotherapy 1,700 1,700 1,700 1,800
    Trastuzumab monotherapy 360 370 360 366
    Trastuzumab with 
paclitaxel or vinorelbine)
1,700 1,740 1,700 1,740
   Anastrozole 790 815 790 811
   Letrozole 990 1,020 990 1,014
    Trastuzumab + hormonal 
therapy
4,300 4,500 4,300 4,170
Total costs (in k€) 7,800*/9,400** 10,900*/12,500** 7,800*/9,400** 10,700*/12,200**
Total LYG 1,500*/1,700** 1,600*/1,700** 1,500*/1,700** 1,600*/1,700**
ICER n/a 71,000*/77,000** n/a 74,000*/80,000**
*If ER+/HER2– patients were treated with Anastrozole and ER-/HER2+ patients were treated with Trastuzumab 
monotherapy;
**If ER+/HER2- patients were treated with Letrozole and ER-/HER2+ patients were treated with Trastuzumab combination 
therapy (trastuzumab and paclitaxel).
n/a – not applicable.
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DISCUSSION
The aim of this study was to assess the potential 
cost-effectiveness of applying PET/CT with FES and 89Zr-
trastuzumab as compared to pathology testing to select 
first-line treatment in MBC patients with non-rapidly 
progressive disease. A previously published and validated 
computer model on metastatic breast cancer simulation 
was extended and applied in this analysis. The intervention 
pathway yielded higher costs to evaluate receptor status 
of the MBC disease and select treatment as compared to 
the care as usual pathway. The number of LYG was also 
higher in the intervention pathway, provided sensitivity 
and specificity were sufficiently high. The application 
of PET/CT with FES and 89Zr-trastuzumab tracers for 
selecting the first-line therapy in MBC had the potential 
to be cost-effective when the sensitivity and the specificity 
of the PET/CT were at least 77.1% and 80% (aiming at 
the lowest sensitivity), or – starting with low values of 
specificity: 80% and 76.7%, respectively. The results of 
this analysis reflected the expected LYG, costs and cost-
effectiveness in MBC patients based on the receptor status 
of their disease (either ER or HER2, or both).
The clinical value of PET/CT has thus far only been 
established with the FDG tracer for detection, staging, 
re-staging and therapy monitoring in various neoplastic 
processes, including breast cancer [18–21]. FDG-PET was 
included in some guidelines for breast cancer work-up, but 
the value of FDG-PET in metastatic breast cancer has been 
debated. FDG-PET could aid the staging of the disease (i.e. 
detect lesions), but it does not provide information about 
the status of the drug targets in the lesions [18–21]. PET/
CT with the FES and the 89Zr-trastuzumab tracers could 
provide a whole-body visualization of metastatic recurrence 
after breast cancer and its ER- and HER2-status. Therefore, 
it has implications for therapy selection, personalized 
treatment and follow-up which may result in increase of 
survival [12–15, 22]. Furthermore, PET/CT with FES 
and 89Zr-trastuzumab could be a valuable alternative in 
situations where biopsy is not feasible. Biopsy could only 
give information about several drug targets in a small part 
of a single lesion. In contrast, PET/CT imaging could give 
information about a few targets in all lesions in the body. 
It is known that discrepancy in target expression between 
lesions in a single patient is observed in a high percentage 
of the patients (10 – 30%) [8–12].
We varied the sensitivity and the specificity of 
PET/CT with FES and 89Zr-trastuzumab from 0 to 100% 
to evaluate different combinations of these at which the 
intervention pathway was likely to be cost-effective. 
The values for sensitivity and specificity in our analysis 
are theoretical and suggest a precision which is not 
reached in daily practice. Previous studies showed a 
high sensitivity of FES-PET (overall 84%), but with 
considerable variability between studies (range 69–100 
%) [14]. This variability was probably due to differences 
in inclusion criteria and the location of lesions. FES-PET/
CT demonstrated high sensitivity in patients with bone 
and lung lesions, and relatively poor sensitivity in patients 
with liver and brain lesions. The specificity of FES-PET/
CT in ER-positive lesions is generally very high in all 
studies (overall 98%) [14]. For 89Zr-trastuzumab PET, 
no sensitivity and specificity data are available yet. Our 
analysis demonstrated that even small increase in the 
sensitivity and the specificity of PET/CT could have a 
large impact on its potential cost-effectiveness. Whether 
the impact of FES-PET/CT and 89Zr-trastuzumab-PET/
CT on treatment selection in MBC would actually result 
in prolonged progression-free and overall survival and 
maintained quality of life is yet to be determined [23].
There are currently few economic evaluations of 
PET/CT which are mainly aimed at assessing its cost-
effectiveness in diagnosing and staging of different 
types of cancers [16, 17, 19–21]. PET/CT with FDG 
tracer was found to be cost-effective in pre-operative 
staging of colorectal cancer, non-small cell lung cancer 
and solitary pulmonary nodes [19–21]. FDG-PET/CT 
was also found beneficial in evaluating the treatment 
response in the follow-up of non-small cell lung cancer 
[20, 21]. Previously, we have demonstrated that FES-
PET/CT can diminish the number of both false positive 
and false negative results when applied as a first choice 
diagnostic to ER-positive MBC patients. In addition, it 
could decrease the number of imaging and pathology tests 
required to diagnose distant relapse [16]. Other studies 
have demonstrated that PET/CT could generate more 
quality-adjusted life years (QALYs) in comparison to the 
standard work-up for diagnosing MBC at an incremental 
cost of ₤29,700 (~ €36,000) per QALY [17]. The limited 
economic evaluations of PET/CT resulted from lack of 
clinical data from randomized controlled trials (RCTs) or 
observational studies which explore the potential of PET/
CT for treatment selection and response monitoring.
This study evaluated the potential cost-effectiveness 
of the application of molecular imaging with PET/CT for 
selecting the first-line treatment in MBC. Although our 
findings clearly demonstrated the potential of PET/CT 
with FES- and 89Zr-trastuzumab tracers to be cost-effective 
when selecting the first-line treatment in MBC patients we 
must be aware of the limitations of this analysis.
We simplified our approach and limited it to a 
“biopsy versus imaging” for receptor status evaluation and 
a few important treatment options to demonstrate proof 
of concept. It should be noted here, that combinations 
of biopsy and imaging, and other treatment options can 
be substituted into the model, if necessary. This study 
is a starting point for further research on more specific 
situations using a more sophisticated model.
The data regarding the inconclusive and unobtainable 
rate of biopsies to detect MBC and reveal receptor status 
were obtained from literature and not from a dedicated RCT 
or cohort study aimed at evaluating these parameters.
Oncotarget19840www.oncotarget.com
The possible treatment combinations were limited 
to those listed in NICE guidance documents, irrespective 
of the recommendation status, and therefore did not 
necessarily reflect therapeutic advances and variety in 
management of MBC patients. Costs of therapies were 
obtained from the NICE guidelines, converted to euros 
according to the 2016 exchange rate and corrected for 
the difference in per capita expenses between the United 
Kingdom and the Netherlands using World data bank 
estimates, that is costs of all therapies were valued in 
2016 euros and used a fixed PPP (Purchasing Power 
Parity) conversion rate, not a fluctuating exchange rate. 
Thus, they were normalized for inflation and exchange 
rate fluctuations.
Another limitation of the current analysis is that the 
data on survival periods were obtained from reviews and 
meta-analyses of RCTs examining the progression-free 
and overall survival after a specified type of treatment. 
These survival periods did not necessarily reflect the 
survival of MBC patients according to the location of 
the distant spread and the breast cancer subtype (luminal 
A, luminal B, luminal/ HER2, HER2-enriched, basal-
like, and triple negative nonbasal). As it is known that 
every cancer subtype demonstrates a distinct pattern 
of metastatic relapse and the location of the metastatic 
spread is associated with notable differences in survival, 
including these probabilities in the model alongside the 
probability of different survival according to the type of 
treatment would allow for a more precise estimation of 
the expected incremental cost-effectiveness. This would 
have implications not only for the improved survival rate 
but for costs as well as MBC patients who survive longer 
would incur additional substantial costs for their end of 
life care and treatment.
Furthermore, we assumed a single number for the 
sensitivity and the specificity of PET/CT for both FES 
and 89Zr-trastuzumab, but it is known that sensitivity and 
specificity are highly dependent on, amongst others, the 
expression levels of the target, the instrumentation and 
the characteristics of the tracer used. Another limitation 
was that a significant fraction of the patients has a 
heterogeneous receptor status between lesions (i.e. some 
lesions are positive, while others are negative). Pathology 
cannot provide information about this heterogeneity. 
On the other hand, little is known about the impact of 
heterogeneity on treatment selection.
We did not take into consideration the complications 
resulting from obtaining invasive pathology tests, which could 
also affect the costs and the quality of life of MBC patients.
Non-responsiveness to selected therapy and adverse 
effects resulting from assigned therapies were also not 
evaluated and these could affect costs and survival, and thus 
cost-effectiveness estimates.
We only considered first-line treatment selection 
in our analysis, therefore, second-line therapies and the 
potential application of molecular imaging for treatment 
selection in second-line and beyond metastatic setting was 
outside the scope of this study.
The uncertainty and the limitations in our study were 
mainly due to the lack of clinical data from RCTs and 
observational studies investigating the role of PET/CT for 
treatment selection in MBC patients. Initial data from other 
studies regarding the sensitivity and the specificity of Zr-
trastuzumab PET demonstrated multiple false positives in 
presumed HER2-negative patients but the sample size was 
small [24]. Part or all of these uncertainties and limitations 
in data availability could be solved when a recent RCT 
aimed at patient-tailored cancer treatment supported by 
molecular imaging is concluded [23]. This would allow to 
explore other premises in which PET/CT would not replace 
pathology in all patients but would be added in specific 
cases.
The application of PET/CT with FES and 89Zr-
trastuzumab as a replacement for care as usual in first-
line treatment selection in MBC patients comes at 
additional costs but has the potential to be a cost-effective 
intervention. The minimum sensitivity and specificity at 
which PET/CT imaging with FES and 89Zr-trastuzumab 
tracers would be cost-effective were estimated at 77.1% 
and 80%, or 80% and 76.7%, respectively. PET/CT 
imaging with FES and 89Zr-trastuzumab tracers could be 
a promising advancement in the treatment selection in 
MBC [22–24]. Our analysis, however, demonstrated that 
even a small increase in the sensitivity and the specificity 
of PET/CT can have a large impact on its potential cost-
effectiveness. As the current analysis has uncertainties 
and limitations resulting from the lack of RCTs’ or cohort 
study clinical data, additional prospective research (in 
terms of more and larger clinical studies) is required 
to validate the role of PET/CT in treatment selection 
and assess the generalizability of the reported benefits, 
particularly given the associated costs of the modality.
MATERIALS AND METHODS
A published and validated computer model on 
metastatic breast cancer simulation (MBCSIM) served 
as a basis for this analysis [16]. The MBCSIM model 
was designed to simulate the follow-up of women after 
initial breast cancer and diagnose MBC in women who 
exhibited symptoms suggestive of distant relapse from the 
Dutch health care perspective. Detailed description of the 
MBCSIM model and its parameters could be found in a 
previous publication [16].
Structure of the model
For this application, we designed a decision tree 
which extended the MBCSIM model by incorporating 
targeted treatment selection components after diagnosing 
the distant relapse. The structure of the current model and 
its parameters are presented in Figure 1 and Table 2. The 
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presence of distant relapse was based on the probability 
of developing MBC and distributed over four locations 
(bone, lung, liver, brain). When MBC was diagnosed, 
the patient followed either a care as usual pathway or an 
intervention pathway involving targeted therapy.
Simulated patient population
We used two hypothetical cohorts of 1000 women 
each to perform the simulations for the care as usual 
and the intervention pathways. The women in each 
cohort were diagnosed and treated for primary breast 
cancer. Within the 5-year period after primary diagnosis 
these women developed distant relapse. The presence of 
metastatic disease was simulated on the basis of the risk 
to develop distant relapse over time and distributed over 
the four most common locations, bone, lung, liver, and 
brain. The receptor status of the primary tumor as well as 
the probability of receptor change in the metastatic disease 
was based on literature. In the simulation, each cohort 
was assigned to either the care as usual or the intervention 
pathway irrespective of the receptor status of the primary 
breast cancer.
Strategies for treatment selection in MBC
Two pathways for selecting targeted treatment in 
MBC patients were compared.
Care as usual pathway
 In the care as usual pathway after being diagnosed 
with MBC, patients were assumed to undergo pathology 
testing to determine the ER- and HER2-expression of 
the biopsied lesions. Then patients were assigned to 
therapy based on the receptor status of their disease 
as determined by the pathology results. Patients with 
metastatic lesions which expressed positive ER and 
positive HER2 status received first-line trastuzumab and 
hormonal therapy (anastrozole). Patients with metastatic 
lesions which expressed positive ER and negative HER2-
status were assigned to first-line hormonal therapy alone 
Figure 1: Flow chart of the decision analytical model.
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(either anastrozole or letrozole). Patients with metastatic 
lesions who tested negative on the ER and positive on 
the HER2-status received first-line trastuzumab (mono 
or combination (trastuzumab and paclitaxel) therapy). 
Patients with metastatic lesions which had negative ER 
and HER2-expression received first-line chemotherapy.
Intervention pathway
In the intervention pathway two PET/CT scans 
with different tracers, FES and 89Zr-trastuzumab, replaced 
pathology testing to establish receptor status of the MBC 
disease, and the relevant therapy was assigned on the basis 
of the PET imaging results.
Parameters of the decision analytical model
The parameters of the model and their baseline, 
minimum and maximum estimates were derived from 
literature (Table 2). The distribution of the locations of 
MBC was obtained from a cohort of patients diagnosed 
with primary disease and subsequently developed 
MBC within a 5-year follow-up [25]. The overall 
survival  estimates were based on meta-analyses and 
RCTs of receptor positive MBC patients treated with 
targeted, hormonal and chemo- therapies [5, 26–30]. 
The inconclusive rate of pathology and the rate of 
unobtainable pathology samples were based on previous 
publications [9–11, 16]. As studies reporting on the 
sensitivity and specificity of PET/CT with different 
tracers were either limited [14, 15, 24] or still in progress 
[23], we chose to vary these parameters independently 
of age and of the location of the MBC to analyze cost-
effectiveness.
Outcomes
The outcomes evaluated were life years gained 
(LYG), costs (diagnosis and treatment related), and 
Table 2: Parameters of the decision analytical model
Baseline estimate
(%)
Minimum 
estimate
(%)
Maximum 
estimate
(%)
Reference
Distribution of location of MBC
25
    Bone 46 25 61
    Lung 40 26 60
    Brain 13 7 28
    Liver 32 24 49
Probability of MBC 
being ER+
62 45 70 7
Probability of MBC 
being ER–
26 23 30 7
Probability of MBC 
being HER2+
18 14 20 8
Probability of MBC 
being HER2–
76 72 80 8
Probability of 
inconclusive pathology
20 10 30 16
Probability of 
unobtainable pathology
20 10 30 9–11
Survival periods (in months)
    after chemotherapy 22.7 20.3 31.9 5, 26–30
     after trastuzumab 
therapy
32.2 25.4 40.8
     after hormonal 
therapy
28.6*/33.2** 17.4*/32.3** 39.2*/34**
     after trastuzumab and 
hormonal therapy
34.1 n/a n/a
*anastrozole, **letrozole, n/a – not available.
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cost-effectiveness (incremental cost-effectiveness ratio – 
ICER).
Health effects
Life years gained were modeled by assigning 
survival periods to the different health states. These 
survival periods were obtained from meta-analyses and 
RCTs which estimated overall survival of MBC patients 
treated with targeted, hormonal and chemo- therapies 
[5, 26–30].
Costs
Only direct costs of imaging tests and treatment 
regimens were included, valued in euros. The costs of the 
imaging and pathology tests were obtained from the tariffs 
level for 2016 (Table 3) [31]. Only Food and Drug Agency 
and European Medicines Agency approved hormonal, 
targeted and chemotherapies were considered for costing. 
The costs of the approved therapies were obtained from 
the National Institute for Health and Care Excellence 
(NICE) guidance reports [32–38], and corrected for the 
difference in per capita expenses between the United 
Kingdom and the Netherlands using World data bank 
estimates from 2015 [39].
Table 3 presents the costs per treatment for the 
whole duration of treatment and the average duration of 
treatment is provided in Appendix B. Detailed description 
of costs and cost calculations is available in Supplementary 
Appendix B. Costs of pathology complications, treatment 
of adverse events or palliative care, and second and third 
line treatment were not taken into account. Discounting 
was not applied due to the relatively short-time horizon 
(less than 5 years) of the analysis.
Cost-effectiveness analyses
A health payer perspective was adopted. The total 
costs of each pathway was calculated by summing the 
costs of all performed tests and the selected treatments. 
The ICER was calculated by dividing the incremental 
cost by the number of incremental LYG. Potential cost-
effectiveness was established by varying the sensitivity 
and the specificity of the PET/CT and assessing the impact 
of these variations on the ICERs.
In the Netherlands, an informal ceiling ratio of 
€ 80,000 per LYG was established by the Dutch Council 
for Public Health and Health Care [40]. This is considered 
a maximum ceiling ratio applicable when there is a high 
burden of disease, as is the case of MBC.
Sensitivity analyses
A univariate sensitivity analysis was performed for 
practical reasons. Since the model has demonstrated to be 
predominantly sensitive to the input parameters related to 
the sensitivity and the specificity of the PET/CT and the 
pathology failure, it was considered that a probabilistic 
sensitivity analysis where all the input parameters were 
Table 3: Costs of imaging and pathology tests, and treatment
Cost in € Reference
Imaging test
   PET whole body 1,144 31
   CT bone 175 31
   CT lung 194 31
   CT brain 145 31
   CT liver 207 31
Pathology test
   Liver 137 31
   Bone/lung/brain 657 31
Treatment options
Trastuzumab monotherapy 9,730 33, 34, 37–39
Trastuzumab combination therapy
(trastuzumab and paclitaxel)
46,080
Trastuzumab + anastrozole 48,512 33, 34, 36–39
Docetaxel 11,015 35, 37–39
Anastrozole 2,141 36, 37–39
Letrozole 2,676 36, 37–39
The treatment costs represent cost per patients for the whole duration of treatment.
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changed at the same time would not provide essentially 
different information. Therefore, univariate sensitivity 
analyses with minimum and maximum values of the 95% 
CI for the input parameters listed in Table 2 for the entire 
cohort of 1,000 women were performed to evaluate the 
effects of parameter uncertainty in each pathway.
Since sensitivity and specificity show a certain trade-
off, we evaluated different combinations of these, setting 
in turn sensitivity or specificity at a pre-specified value 
and then varying the remaining parameter. We analyzed 
the values at which the intervention was just cost-effective 
(at €80,000 per LYG), effective (had positive LYG) and 
some fixed values below and above these values, to gain 
insight into the changes in incremental cost-effectiveness 
of the intervention as compared to the care as usual, for 
three different values of biopsy failure probability. We used 
values of 77.4% for sensitivity and 80% for specificity in 
the baseline scenario 1 and 80% and 76.7%, respectively, 
for baseline 2 to calculate the point estimate for the cost-
effectiveness. The sensitivity of FES-PET/CT ranges 
between 69% and 100% and the specificity varies between 
80% and 100% [14]. For the sensitivity analyses we applied 
a fixed sensitivity and varying specificity of PET/CT 
(Supplementary Table A1) as well as a fixed specificity and 
varying sensitivity (Supplementary Table A2) to estimate 
the sensitivity of the ICER resulting from the error margins 
in the PET/CT sensitivity and specificity.
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